Cargando…

Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy

In late 2019, COVID-19 emerged in Wuhan, China. Currently, it is an ongoing global health threat stressing the need for therapeutic compounds. Linking the virus life cycle and its interaction with cell receptors and internal cellular machinery is key to developing therapies based on the control of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Susana, Barata, Pedro, Charmier, Adilia, Lehmann, Inês, Rodrigues, Suzilaine, Melosini, Matteo M., Pais, Patrick J., Sousa, André P., Teixeira, Catarina, Santos, Inês, Rocha, Ana Catarina, Baylina, Pilar, Fernandes, Ruben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886108/
https://www.ncbi.nlm.nih.gov/pubmed/35242142
http://dx.doi.org/10.3389/fimmu.2022.841459
_version_ 1784660579099607040
author Santos, Susana
Barata, Pedro
Charmier, Adilia
Lehmann, Inês
Rodrigues, Suzilaine
Melosini, Matteo M.
Pais, Patrick J.
Sousa, André P.
Teixeira, Catarina
Santos, Inês
Rocha, Ana Catarina
Baylina, Pilar
Fernandes, Ruben
author_facet Santos, Susana
Barata, Pedro
Charmier, Adilia
Lehmann, Inês
Rodrigues, Suzilaine
Melosini, Matteo M.
Pais, Patrick J.
Sousa, André P.
Teixeira, Catarina
Santos, Inês
Rocha, Ana Catarina
Baylina, Pilar
Fernandes, Ruben
author_sort Santos, Susana
collection PubMed
description In late 2019, COVID-19 emerged in Wuhan, China. Currently, it is an ongoing global health threat stressing the need for therapeutic compounds. Linking the virus life cycle and its interaction with cell receptors and internal cellular machinery is key to developing therapies based on the control of infectivity and inflammation. In this framework, we evaluate the combination of cannabidiol (CBD), as an anti-inflammatory molecule, and terpenes, by their anti-microbiological properties, in reducing SARS-CoV-2 infectivity. Our group settled six formulations combining CBD and terpenes purified from Cannabis sativa L, Origanum vulgare, and Thymus mastichina. The formulations were analyzed by HPLC and GC-MS and evaluated for virucide and antiviral potential by in vitro studies in alveolar basal epithelial, colon, kidney, and keratinocyte human cell lines. CONCLUSIONS AND IMPACT: We demonstrate the virucide effectiveness of CBD and terpene-based formulations. F2TC reduces the infectivity by 17%, 24%, and 99% for CaCo-2, HaCat, and A549, respectively, and F1TC by 43%, 37%, and 29% for Hek293T, HaCaT, and Caco-2, respectively. To the best of our knowledge, this is the first approach that tackles the combination of CBD with a specific group of terpenes against SARS-CoV-2 in different cell lines. The differential effectiveness of formulations according to the cell line can be relevant to understanding the pattern of virus infectivity and the host inflammation response, and lead to new therapeutic strategies.
format Online
Article
Text
id pubmed-8886108
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88861082022-03-02 Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy Santos, Susana Barata, Pedro Charmier, Adilia Lehmann, Inês Rodrigues, Suzilaine Melosini, Matteo M. Pais, Patrick J. Sousa, André P. Teixeira, Catarina Santos, Inês Rocha, Ana Catarina Baylina, Pilar Fernandes, Ruben Front Immunol Immunology In late 2019, COVID-19 emerged in Wuhan, China. Currently, it is an ongoing global health threat stressing the need for therapeutic compounds. Linking the virus life cycle and its interaction with cell receptors and internal cellular machinery is key to developing therapies based on the control of infectivity and inflammation. In this framework, we evaluate the combination of cannabidiol (CBD), as an anti-inflammatory molecule, and terpenes, by their anti-microbiological properties, in reducing SARS-CoV-2 infectivity. Our group settled six formulations combining CBD and terpenes purified from Cannabis sativa L, Origanum vulgare, and Thymus mastichina. The formulations were analyzed by HPLC and GC-MS and evaluated for virucide and antiviral potential by in vitro studies in alveolar basal epithelial, colon, kidney, and keratinocyte human cell lines. CONCLUSIONS AND IMPACT: We demonstrate the virucide effectiveness of CBD and terpene-based formulations. F2TC reduces the infectivity by 17%, 24%, and 99% for CaCo-2, HaCat, and A549, respectively, and F1TC by 43%, 37%, and 29% for Hek293T, HaCaT, and Caco-2, respectively. To the best of our knowledge, this is the first approach that tackles the combination of CBD with a specific group of terpenes against SARS-CoV-2 in different cell lines. The differential effectiveness of formulations according to the cell line can be relevant to understanding the pattern of virus infectivity and the host inflammation response, and lead to new therapeutic strategies. Frontiers Media S.A. 2022-02-15 /pmc/articles/PMC8886108/ /pubmed/35242142 http://dx.doi.org/10.3389/fimmu.2022.841459 Text en Copyright © 2022 Santos, Barata, Charmier, Lehmann, Rodrigues, Melosini, Pais, Sousa, Teixeira, Santos, Rocha, Baylina and Fernandes https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Santos, Susana
Barata, Pedro
Charmier, Adilia
Lehmann, Inês
Rodrigues, Suzilaine
Melosini, Matteo M.
Pais, Patrick J.
Sousa, André P.
Teixeira, Catarina
Santos, Inês
Rocha, Ana Catarina
Baylina, Pilar
Fernandes, Ruben
Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy
title Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy
title_full Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy
title_fullStr Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy
title_full_unstemmed Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy
title_short Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy
title_sort cannabidiol and terpene formulation reducing sars-cov-2 infectivity tackling a therapeutic strategy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886108/
https://www.ncbi.nlm.nih.gov/pubmed/35242142
http://dx.doi.org/10.3389/fimmu.2022.841459
work_keys_str_mv AT santossusana cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy
AT baratapedro cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy
AT charmieradilia cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy
AT lehmannines cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy
AT rodriguessuzilaine cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy
AT melosinimatteom cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy
AT paispatrickj cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy
AT sousaandrep cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy
AT teixeiracatarina cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy
AT santosines cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy
AT rochaanacatarina cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy
AT baylinapilar cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy
AT fernandesruben cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy